Press release content from Business Wire. The AP news staff was not involved in its creation.
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
January 25, 2021 GMT
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Jan 25, 2021--
Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing.
This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures.